Influence of treatment with ultralow-dose aspirin on platelet aggregation as measured by whole blood impedance aggregometry and platelet P-selectin expression in clinically normal dogs

American Journal of Veterinary Research

Volumn 71, Issue 11, 2010, Pages 1294-1304

  Sharpe, Kristopher S ^a,b   Center, Sharon A ^a   Randolph, John F ^a   Brooks, Marjory B ^a   Warner, Karen L ^a   Stokol, Tracy ^a   Barr, Stephen C ^a   Felippe, M Julia ^a  

^a Department of Molecular Biology and Genetics   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CD61 ANTIGEN; CITRATE SODIUM; COLLAGEN; EDETIC ACID; FLUORESCEIN ISOTHIOCYANATE; PADGEM PROTEIN; PHYCOERYTHRIN; THROMBIN;

ANIMAL EXPERIMENT; ARTICLE; DOG; FEMALE; FLOW CYTOMETRY; HEMOLYTIC ANEMIA; IMPEDANCE; LOW DRUG DOSE; MALE; NONHUMAN; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ANIMALS; ASPIRIN; BLOOD PLATELETS; BODY COMPOSITION; BODY WEIGHT; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; MALE; ORCHIECTOMY; OVARIECTOMY; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES;

ANIMALIA; CANIS FAMILIARIS;

EID: 78149383457     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.71.11.1294     Document Type: Article

References (65)

1. Weinkle TK, Center SA, Randolph JF, et al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc 2005;226:1869-1880.
2. Klein MK, Dow SW, Rosychuck RAW. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987). J Am Vet Med Assoc 1989;195:246-250.
3. McManus PM, Craig LE. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). J Am Vet Med Assoc 2001;218:1308-1313.
4. Scott-Moncrieff JC, Treadwell NG, McCollough SM, et al. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2001;37:220-227.
5. Weiss DJ, Brazzell JL. Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med 2006;20:682-686.
6. Pulmonary embolism prevention trial collaborative group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet 2000;355:1295-1302.
7. Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med 2002;346:1468-1474.
8. Spencer FA, Santopinto JJ, Gore JM, et al. Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (the global registry of acute coronary events [GRACE]). Am J Cardiol 2002;90:1056-1061.
9. Jackson SP. The growing complexity of platelet aggregation. Blood 2007;109:5087-5095.
10. Nesbitt WS, Westein E, Tovar-Lopez FJ, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009;15:655-673.
11. Faxon DP. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices. Rev Cardiovasc Med 2005;6(suppl 4):S3-S14.
12. Stashenko GJ, Tapson VF. Prevention of venous thromboembolism in medical patients and outpatients. Nat Rev Cardiol 2009;6:356-363.
13. Wakefield TW, Caprini J, Comerota AJ. Thromboembolic diseases. Curr Probl Surg 2008;45:844-899.
14. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
15. Griebsch C, Arndt G, Raila J, et al. C-reactive protein concentration in dogs with primary immune-mediated hemolytic anemia. Vet Clin Pathol 2009;38:421-425.
16. Malinin AI, Atar D, Callahan KP, et al. Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur J Pharm 2003;462:139-143.
17. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004;114:447-453.
18. Johnson GJ, Leis LA, Rao GH, et al. Arachidonate induced platelet aggregation in the dog. Thromb Res 1979;65:578-580.
19. Johnson GJ, Rao GHR, Leis LA, et al. Effect of agents that alter cyclic AMP on arachidonate-induced platelet aggregation in the dog. Blood 1980;55:722-729.
20. Johnson GJ, Leis LA, Dunlop PC. Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G protein dysfunction. J Clin Invest 1993;92:2469-2479.
21. Johnson GJ, Leis LA, King RA. Thromboxane responsiveness of dog platelets is inherited as an autosomal recessive trait. Thromb Haemost 1991;65:578-580.
22. Clemmons RM, Meyers KM. Acquisition and aggregation of canine blood platelets: basic mechanisms of function and differences because of breed origin. Am J Vet Res 1984;45:137-144.
23. Yeo EL, Gemmel CH, Sutherland DR, et al. Characterization of canine platelet P-selectin (CD62) and its utility in flow cytometry platelet studies. Comp Biochem Physiol 1993;105B:625-636.
24. Boudreaux MK, Panangala VS, Bourne C. A platelet activation-specific monoclonal antibody that recognizes a receptor induced binding site on canine fibrinogen. Vet Pathol 1996;33:419-427.
25. Weiss DJ, Mirsky ML, Evanson OA, et al. Platelet kinetics in dogs treated with a glycoprotein IIb/IIIa peptide antagonist. Toxicol Pathol 2000;28:310-316.
26. Hamburger SA, McEvers RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990;75:550-558.
27. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996;93:11877-11882.
28. Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20.
29. Boneu B, Fernandez F. The role of the hematocrit in bleeding. Transfus Med Rev 1987;1:182-185.
30. Hayward CP, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-319.
31. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008;34:709-733.
32. Brooks MB, Catalfamo JL, Brown HA, et al. A hereditary bleeding disorder of dogs caused by a lack of platelet procoagulant activity. Blood 2002;99:2434-2441.
33. Brooks MB, Randolph JF, Warner K, et al. Evaluation of platelet function screening tests to detect platelet procoagulant deficiency in dogs with Scott syndrome. Vet Clin Pathol 2009;38:306-315.
34. Moritz A, Walcheck BK, Weiss DJ. Evaluation of flow cytometric and automated methods for detection of activated platelets in dogs with inflammatory disease. Am J Vet Res 2005;66:325-329.
35. Rukshin V, Azarbal B, Finkelstein A, et al. Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis. J Cardiovasc Pharmacol 2003;41:615-624.
36. Wills TB, Wardrop KJ, Meyers KM. Detection of activated platelets in canine blood by use of flow cytometry. Am J Vet Res 2006;67:56-63.
37. Tarnow I, Kristensen AT, Krogh AK, et al. Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. Vet Immunol Immunopathol 2008;123:345-352.
38. Schuberth H-J, Kucinskiene G, Chu R-M, et al. Reactivity of cross-reacting monoclonal antibodies with canine leukocytes, platelets, and erythrocytes. Vet Immunol Immunopathol 2007;119:47-55.
39. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apheresis Sci 2003;28:307-317.
40. Brainard BM, Meredith CP, Callan MB, et al. Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs. Am J Vet Res 2007;68:251-257.
41. Grauer GF, Rose BJ, Toolan L, et al. Effects of low-dose aspirin and specific thromboxane synthetase inhibition on whole blood platelet aggregation and adenosine triphosphate secretion in healthy dogs. Am J Vet Res 1992;53:1631-1635.
42. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003;102:449-461.
43. Quinton TM, Dangelmaier C, Daniel JL, et al. Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKC-sensitive pathways without a requirement for secreted ADP. Blood 2002;99:3228-3234.
44. Hwang DH. Species variation in platelet aggregation. In: Longenecker GL, ed. The platelets: physiology and pharmacology. New York: Academic Press Inc, 1985;289-305.
45. Boudreaux MK, Dillon AR, Ravis WR, et al. Effects of treatment with aspirin or aspirin/dipyridamole combination in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs. Am J Vet Res 1991;52:1992-1999.
46. Ruf A, Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-selectin expression. Semin Thromb Hemost 1995;21:146-151.
47. Li N, Goodall AH, Hjemdahl P. Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry 1999;35:154-161.
48. Caron A, Theoret JF, Mousa SA, et al. Antiplatelet effects of GPIIb-IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils. J Cardiovasc Pharmacol 2002;40:296-306.
49. Moritz A, Walcheck BK, Weiss DJ. Flow cytometric detection of activated platelets in the dog. Vet Clin Pathol 2003;32:6-12.
50. Rinder CS, Student LA, Bonan JL, et al. Aspirin does not inhibit adenosine diphosphate-induced platelet α-granule release. Blood 1993;82:505-515.
51. Rand ML, Perry DW, Packham MA, et al. Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of β-thromboglobulin and assessment by flow cytometry of P-selectin expression. Am J Hematol 1996;52:288-294.
52. Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003;111:165-170.
53. O'Flaherty JT, Cousart S, Lineberger AS, et al. Phorbol myristate acetate: in vivo effects on neutrophils, platelets, and lung. Am J Pathol 1980;101:79-92.
54. Chen R, Liang N. Cytoskeletal changes in platelets induced by thrombin and phorbol myristate acetate (PMA). Cell Biol Int 1998;22:429-435.
55. Klinkhardt U, Harder S. Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function? Semin Thromb Hemost 2005;31:400-403.
56. McKenzie ME, Malinin AI, Bell CR, et al. Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD-63, CD-107a receptor expression on human platelets. Blood Coagul Fibrinolysis 2003;14:249-253.
57. Klinger MHF. Platelets and inflammation. Anat Embryol (Berl) 1997;196:1-11.
58. Klinger MHF, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002;22:913-922.
59. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349-356.
60. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am J Med 2001;110:62S-65S.
61. Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 1991;87:571-580.
62. Valles J, Santos MT, Aznar J, et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood 1991;78:154-162.
63. Lopez-Farre A, Caramelo C, Esteban A, et al. Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1. Circulation 1995;91:2080-2088.
64. Santos MT, Valles J, Aznar J, et al. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation 1997;95:63-68.
65. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 2002;105:2600-2604.